Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb;13(2):465-476.
doi: 10.1007/s13555-022-00867-y. Epub 2022 Dec 6.

Long-Term Effectiveness and Drug Survival of Secukinumab in Vietnamese Patients with Psoriasis: Results from a Retrospective ENHANCE Study

Hao Trong Nguyen  1 , Nhi Thi Uyen Pham  2 , Tu Nguyen Anh Tran  2 , Nguyen Nhat Pham  2 , Yen Thi Bui  3 , Thao Thi Phuong Vu  2
Affiliations

Long-Term Effectiveness and Drug Survival of Secukinumab in Vietnamese Patients with Psoriasis: Results from a Retrospective ENHANCE Study

Hao Trong Nguyen et al. Dermatol Ther (Heidelb). 2023 Feb.

Erratum in

Abstract

Introduction: Psoriasis (PsO), an immune-mediated inflammatory skin disorder, has substantial negative impact on patients' quality of life. Secukinumab, an approved treatment for moderate-to-severe plaque PsO, has an established long-term efficacy and safety profile. This study aims to provide real-world evidence of long-term effectiveness and retention rate of secukinumab in Vietnamese patients with PsO.

Methods: This retrospective, observational study collected medical records of adult patients with moderate-to-severe PsO receiving secukinumab treatment from Ho Chi Minh City Hospital of Dermato-Venereology. The primary objective was to evaluate secukinumab effectiveness in PsO as measured by 75% improvement in psoriasis area and severity index (PASI 75) at month 12. Secondary objectives were PASI 90/100, absolute PASI ≤ 3 and ≤ 5, Dermatology Life Quality Index (DLQI), and retention rate over 48 months.

Results: In total, 232 patients with moderate-to-severe PsO met inclusion criteria; 68.1% were male, with median age and age of onset of 39 and 27.5 years, respectively. Median time from onset of PsO to secukinumab treatment was 120 months, 95.3% were prior biologics/disease-modifying antirheumatic drugs naive and 41.4% received concomitant therapies for PsO; 82.3% had national insurance coverage. At month 12, 93.9% of patients achieved PASI 75 (primary endpoint); 80.2/56.9% achieved PASI 90/100; 91.4 and 84.8% patients achieved absolute PASI ≤ 5 and ≤ 3, respectively. The response was sustained over 48 months, with 91.9%/78.0%/52.0% of patients achieving PASI 75/90/100, 89.5% and 82.1% patients achieving absolute PASI ≤ 5 and ≤ 3, respectively. At month 12, 61.4% of patients achieved DLQI 0/1 which was sustained up to month 48 (69.2%). Secukinumab adherence rate of 84.9% at month 12 dropped to 34.2% at month 48. Patients receiving concomitant therapy and national insurance showed higher adherence rate.

Conclusion: Secukinumab demonstrated long-term effectiveness in real-world Vietnamese patients with moderate-to-severe PsO, with treatment adherence being higher in patients having concomitant therapies and national insurance.

Keywords: Biologics; Effectiveness; Psoriasis; Real-world; Secukinumab.

PubMed Disclaimer

Conflict of interest statement

Hao T. Nguyen has served as an advisory board member and speaker for Novartis, Janssen, and Menarini. Nhi T. U. Pham, Tu N. A. Tran, and Thao T. P. Vu have served as a speaker for Novartis, Janssen, and Menarini. Yen T. Bui is an employee of Novartis Vietnam Co., Ltd. Nguyen N. Pham has nothing to disclose.

Figures

Fig. 1
Fig. 1
Study design
Fig. 2
Fig. 2
Proportion of patients achieving PASI 75, PASI 90, PASI 100, PASI ≤ 5 and PASI ≤ 3. PASI psoriasis area and severity index
Fig. 3
Fig. 3
A Rate of achieving DLQI 0/1 over 48 months of secukinumab treatment. B Change in DLQI over 48 months of secukinumab treatment. DLQI dermatology life quality index
Fig. 4
Fig. 4
Adherence rate to secukinumab treatment over 48 months
Fig. 5
Fig. 5
Kaplan–Meier secukinumab drug survival curve
See this image and copyright information in PMC

References

    1. Boehncke WH, Schon MP. Psoriasis Lancet. 2015;386(9997):983–994. doi: 10.1016/S0140-6736(14)61909-7. - DOI - PubMed
    1. Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590. doi: 10.1136/bmj.m1590. - DOI - PMC - PubMed
    1. Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker J. Psoriasis Lancet. 2021;397(10281):1301–1315. doi: 10.1016/S0140-6736(20)32549-6. - DOI - PubMed
    1. Thaci D, Korber A, von Kiedrowski R, Bachhuber T, Melzer N, Kasparek T, et al. Secukinumab is effective in treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and safety from the PROSPECT study. J Eur Acad Dermatol Venereol. 2020;34(2):310–318. doi: 10.1111/jdv.15962. - DOI - PubMed
    1. Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, et al. Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338. doi: 10.1056/NEJMoa1314258. - DOI - PubMed

LinkOut - more resources